During their session at Asembia’s AXS24, Sarah Butler and Lindsay Greenleaf of ADVI Health will examine the current status of ...
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) ...
Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening ...
Vitamin D supplementation may decrease in-hospital and intensive care unit (ICU) mortality in patients with chronic ...
UGT2B17, a metabolic enzyme known for regulating various endogenous molecules, has been identified to have heightened ...
A retrospective analysis out of Denmark could not find a causal relationship to explain trends in melanoma incidence and ...
While behavioral health care utilization has been rising, the treatment landscape has been falling. New findings show that 20 ...
Asembia AXS24, which has record registration this year, will take place in Las Vegas, Nevada, April 28-May 2, at the Wynn & ...
Yael Mauer, MD, MPH, discusses the patient population who benefits most from interventions with glucagon-like peptide-1 ...
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez; Pfizer), a gene therapy administered in a one-time dose, for ...
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially ...
Stacey Ehrenberg, MD, discusses the lacking data and potential implications of using glucagon-like peptide-1 (GLP-1) receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results